The Liver Meeting® 2018 ePosters: Hepatitis B

  • LB-14: A Nasal Administrative Therapeutic Vaccine (NASVAC) with Modified Treatment Strategy Reduces and Eliminates Hbs Antigen in HBV Infected Patients with or without Nucleos(t)Ide Analogs Therapy
    Author: Osamu Yoshida
    You must log in to access content.
  • LB-32: Mirna-548ah Promotes the Replication and Expression of Hepatitis B Virus By Targeting Histone Deacetylase-4
    Author: Tongjing Xing
    You must log in to access content.
  • 382: HBsAg Clearance in Patients with Chronic Hepatitis B: Durability and Recurrence Factors
    Authors: Yali Wu, Nan Geng, Yali Liu, Junfeng Lu, Zhenhuan Cao, Lina Ma, Chengli Shen, Xinyue Chen, Yi Jin
    You must log in to access content.
  • 383: Inarigivir Is a Novel Selective Inhibitor of the HBV Replicase Complex in Vitro
    Authors: Stephen Locarnini, Kathy Jackson, Michael Beard, Nezam Afdhal, Radhakrishnan Iyer, Haitao Guo, Vitina Sozzi, Xin Li, Nicholas Eyre, Junjie Zhang, Danni Colledge
    You must log in to access content.
  • 384: On-Treatment ALT Normalization Has No Statistical Significant Impact on Liver Stiffness Regression in Chinese Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis Receiving Tenofovir Disoproxil Fumarate Therapy
    Authors: Lai Wei, Jia Shang, Qing Xie, Zhansheng Jia, Pujun Gao, Junping Shi, Xinyue Chen, Jiefei Wang, Min Xu, Liaoyun Zhang, Yingren Zhao, Maorong Wang, Qing Mao, Wei Zhao, Zong Zhang, Jidong Jia, Hong Tang, Jiming Zhang, Xin Zheng, Cui Xiong, Mingfen Zhu
    You must log in to access content.
  • 385: Hsu YC, et al., Aliment Pharmacol Ther. 2018 [in press] Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B
    Authors: Yao-Chun Hsu, Tomi Jun, Yen-Tsung Huang, Ming-Lun Yeh, Jaw-Town Lin, Ming-Lung Yu, Mindie Nguyen, Yasuhito Tanaka
    You must log in to access content.
  • 389: Effectiveness of Response-Guided Peginterferon Alfa-2a Therapy in Nucleos(t)Ide Analogues Treated Patients with Hbeag-Positive Chronic Hepatitis B: Interim Analysis of a Prospective, Multicenter, Randomized Study
    Authors: Wei Cai, Qing Xie, Lijuan Ouyang, Yueqiu Gao, Shibo Li, Jie Xu, Chuanwu Zhu, Jianchun Xian, Guizhou Zou, Yue-Yong Zhu, Guancheng Huang
    You must log in to access content.
  • 391: Long-Term Efficacy of Tenofovir Disoproxil Fumarate Monotherapyfor Multidrug-Resistant Chronic Hepatitis B
    Authors: Hye Won Lee, Junyong Park, Jin-Woo Lee, Ki Tae Yoon, Chang Wook Kim, Hana Park, Young Seok Kim, Jung Il Lee, Soon Koo Baik, Sang Hoon Ahn, Beom Kyung Kim, Kwang-Hyub Han
    You must log in to access content.
  • 393: Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of Hbeag Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2a
    Authors: Liviu Iarovoi, Michel Bazinet, Gheorghe Placinta, Andrew Vaillant, Victor Pântea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Valentina Smesnoi, Tatiana Musteata, Iurie Moscalu, Alina Jucov, Adalbert Krawczyk
    You must log in to access content.
  • 396: Impact of Steatosis on Fibrosis Progression in Chronic Hepatitis B Patients: Results from 239 Paired Liver Biopsies before and after Anti-Viral Therapy
    Authors: Yameng Sun, Xiaoning Wu, Xinyan Zhao, Jialing Zhou, Shanshan Wu, Bingqiong Wang, Yiwen Shi, Shuyan Chen, Xiaojuan Ou, Jidong Jia, Hong You, Yuanyuan Kong
    You must log in to access content.
  • 397: Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk
    Authors: Yao-Chun Hsu, Mindie Nguyen, Lien-Juei Mou, Ming-Shiang Wu, Tzeng-Huey Yang, Chieh-Chang Chen, Cheng-Hao Tseng, Chi-Ming Tai, Chun-Ying Wu, Jaw-Town Lin, Yasuhito Tanaka, Chi-Yang Chang
    You must log in to access content.
  • 399: Early Quantitative Response of Hepatitis B Surface Antigen Is Associated with Seroclearance in Patients with Chronic Hepatitis B during Nucleot(s)Ide Analog Therapy
    Authors: Murata Ayato, Takuya Genda, Shunsuke Sato, Sho Sato, Nozomi Amano, Hironori Tsuzura, Ko Tomishima, Kohei Matsumoto, Yuji Shimada, Katsuyori Iijima, Masashi Mori
    You must log in to access content.
  • 400: Nucleoside Analogue Therapy in Acute Hepatitis B Infection: A Retrospective Review of 8 Years of Experience from King’s College Hospital
    Authors: Thomas Tranah, Peter Foulser, Ivana Carey, Kosh Agarwal, Abid Suddle, Sarah Brown, William Bernal, Geoffrey Dusheiko
    You must log in to access content.
  • 402: In Vitro Antiviral Activity and Mode of Action of JNJ-64530440, a Novel Potent Hepatitis B Virus Capsid Assembly Modulator in Clinical Development
    Authors: Jan Martin Berke, Thierry Verbinnen, Karen Vergauwen, Pascale Dehertogh, Sandrine Vendeville, Pierre Raboisson, Frederik Pauwels
    You must log in to access content.
  • 406: Variance between Experts and Community Clinicians in Treatment of Chronic Hepatitis B Infection
    Authors: Jenny Schulz, Zachary Schwartz, Edward King, Robert Brown, Jordan Feld, Natalie Bzowej, Norah Terrault
    You must log in to access content.
  • 407: Serum Hepatitis B Core-Related Antigen Can Predict Hbeag Seroconversion in Chronic Hepatitis B Patients
    Authors: Junqi Niu, Xiumei CHI, Zhongfeng Wang, Ruihong Wu, Xiaomei Wang, Xiuzhu Gao, Hongqin Xu
    You must log in to access content.
  • 408: Predictability of Serum Hbcrag, HBsAg and Interferon Inducible Protein 10 (IP10) Levels in Non-Cirrhotic Hbeag-Negative Chronic Hepatitis B Patients Who Discontinue Entecavir (ETV) or Tenofovir (TDF) Therapy: Results from the Prospective Daring-B Stu
    Authors: George Papatheodoridis, Margarita Papatheodoridi, Emilia Hadziyannis, Francoise Berby, Eirini Rigopoulou, Kalliopi Zachou, Barbara Testoni, Aggeliki Lyberopoulou, Nikolaos Gatselis, Ioannis Vlachogiannakos, Spilios Manolakopoulos, George Dalekos, Fabien Zoulim
    You must log in to access content.
  • 410: Efficacy and Renal Safety of Long-Term Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Normal or Mild Renal Dysfunction (eGFR ≥60 mL/min/1.73m2)
    Authors: Chang Hun Lee, In Hee KIM, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee
    You must log in to access content.
  • 419: Outcomes of the first 51 patients at 48 weeks in the HBV-STOP study, a prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients who have achieved long term virological suppression
    Authors: Samuel Hall, Gareth Burns, Miriam Levy, John Lubel, Amanda Nicoll, Gail Matthews, Paul Desmond, William Sievert, Scott Bowden, Stephen Locarnini, Kumar Visvanathan, Alexander Thompson
    You must log in to access content.
  • 420: Controlled Attenuation Parameter but Not PNPLA3 Polymorphism Is the Independent Factor of Abnormal ALT after Well Viral Suppression in Chronic Hepatitis B Infection Patients
    Authors: Hung-Chih Chiu, Ting-Tsung Chang, Yen-Cheng Chiu, I-Chih Wu, Pin-Nan Cheng
    You must log in to access content.